BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Department of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On April 13, 2017, Dr. Chia Soo and Dr. Ben Wu resigned as
directors of the Company. They also resigned as members of
Companys Scientific Advisory Board. The reasons for their
resignations are set forth in their notice of resignation which
is attached as Exhibit 17. The notice describes their
disagreements with the Company.
The Company has provided Drs. Soo and Wu with a copy of the
disclosures set forth herein and provided them with an
opportunity to furnish to the Company as promptly as possible a
letter stating whether they agree with such disclosures and, if
not, stating the respects in which he or she does not agree.
The Companys present Board of Directors has decided to reduce the
size of the Board to five members.
|Item 9.01||Financial Statements and Exhibits|
There is filed as part of this report the exhibit listed on the
accompanying Index to Exhibits, which information is incorporated
herein by reference.
|Notice of Resignation|
About BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG)
Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company’s platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company’s platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX. BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Recent Trading Information
BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) closed its last trading session down -0.40 at 1.50 with 150 shares trading hands.